Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease with sudden onset symptoms, including nerve damage affecting movement, sensation, speech, breathing, and heart rhythm. Treatments such as glucocorticoids, plasmapheresis, and intravenous gamma globulin (IVIG) can help manage symptoms but cannot completely eradicate the disease. However, a research team has reported using BCMA-CD19 bispecific CAR-T cells to treat relapsed/refractory CIDP, restoring the balance of immune responses by temporarily and profoundly eradicating B cells and plasma cells. After being treated with this therapy, one patient made significant progress in functioning according to the INCAT disability and MRC scores. Remarkably, almost complete recovery of muscle power was observed 180 days after administration of CAR-T, along with the ability to walk again. This study, therefore, highlights the evolution of patients’ symptoms after treatment and confirms the safety of CAR-T cell therapy for CIDP.
